My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 399

    1.

    Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial.

    Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC, Champlin RE.

    Ann Intern Med. 1993 Feb 1;118(3):179-84.PMID: 8380243 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant.

    Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD.

    Ann Intern Med. 1993 Feb 1;118(3):173-8.PMID: 8380242 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation.

    Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF, Buhles WC, DeArmond B, Meyers JD.

    N Engl J Med. 1991 Dec 5;325(23):1601-7.PMID: 1658652 [PubMed - indexed for MEDLINE]Related articles

    4.

    Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebo-controlled trial.

    Reed EC, Wolford JL, Kopecky KJ, Lilleby KE, Dandliker PS, Todaro JL, McDonald GB, Meyers JD.

    Ann Intern Med. 1990 Apr 1;112(7):505-10.PMID: 2156476 [PubMed - indexed for MEDLINE]Related articles

    5.

    Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.

    Noble S, Faulds D.

    Drugs. 1998 Jul;56(1):115-46. Review.PMID: 9664203 [PubMed - indexed for MEDLINE]Related articles

    6.

    Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study.

    Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA.

    Blood. 1996 Nov 15;88(10):4063-71.PMID: 8916975 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Management of allogeneic bone marrow transplant recipients at risk for cytomegalovirus disease using a surveillance bronchoscopy and prolonged pre-emptive ganciclovir therapy.

    Reddy V, Hao Y, Lipton J, Meharchand J, Minden M, Mazzulli T, Chan C, Messner HA.

    J Clin Virol. 1999 Aug;13(3):149-59.PMID: 10443791 [PubMed - indexed for MEDLINE]Related articles

    8.

    A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group.

    Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA.

    N Engl J Med. 1991 Apr 11;324(15):1005-11.PMID: 1848679 [PubMed - indexed for MEDLINE]Related articles

    9.

    A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation.

    Merigan TC, Renlund DG, Keay S, Bristow MR, Starnes V, O'Connell JB, Resta S, Dunn D, Gamberg P, Ratkovec RM, et al.

    N Engl J Med. 1992 Apr 30;326(18):1182-6.PMID: 1313549 [PubMed - indexed for MEDLINE]Related articles

    10.

    Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients.

    von Bueltzingsloewen A, Bordigoni P, Witz F, Bene MC, Schmitt C, Lacour B, Sommelet D.

    Bone Marrow Transplant. 1993 Sep;12(3):197-202. Erratum in: Bone Marrow Transplant 1994 Feb;13(2):232. PMID: 8241976 [PubMed - indexed for MEDLINE]Related articles

    11.

    Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients.

    Winston DJ, Wirin D, Shaked A, Busuttil RW.

    Lancet. 1995 Jul 8;346(8967):69-74.PMID: 7603215 [PubMed - indexed for MEDLINE]Related articles

    12.

    Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.

    Burns LJ, Miller W, Kandaswamy C, DeFor TE, MacMillan ML, Van Burik JA, Weisdorf DJ.

    Bone Marrow Transplant. 2002 Dec;30(12):945-51.PMID: 12476289 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]

    Gane E, Saliba F, Valdecasas GJ, O'Grady J, Pescovitz MD, Lyman S, Robinson CA.

    Lancet. 1997 Dec 13;350(9093):1729-33. Erratum in: Lancet 1998 Feb 7;351(9100):454. PMID: 9413463 [PubMed - indexed for MEDLINE]Related articles

    14.

    Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.

    Winston DJ, Busuttil RW.

    Transplantation. 2003 Jan 27;75(2):229-33.PMID: 12548129 [PubMed - indexed for MEDLINE]Related articles

    15.

    Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation.

    Przepiorka D, Ippoliti C, Panina A, Goodrich J, Giralt S, van Besien K, Mehra R, Deisseroth AB, Andersson B, Luna M, et al.

    Bone Marrow Transplant. 1994 Apr;13(4):461-4.PMID: 8019472 [PubMed - indexed for MEDLINE]Related articles

    16.

    Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.

    Boeckh M, Bowden RA, Storer B, Chao NJ, Spielberger R, Tierney DK, Gallez-Hawkins G, Cunningham T, Blume KG, Levitt D, Zaia JA.

    Biol Blood Marrow Transplant. 2001;7(6):343-51.PMID: 11464977 [PubMed - indexed for MEDLINE]Related articles

    17.

    Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis.

    Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR.

    Blood. 1994 Apr 1;83(7):1971-9.PMID: 8142663 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.

    Canpolat C, Culbert S, Gardner M, Whimbey E, Tarrand J, Chan KW.

    Bone Marrow Transplant. 1996 Apr;17(4):589-93.PMID: 8722360 [PubMed - indexed for MEDLINE]Related articles

    19.

    Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors.

    Winston DJ, Busuttil RW.

    Transplantation. 2004 Jan 27;77(2):305-8.PMID: 14742998 [PubMed - indexed for MEDLINE]Related articles

    20.

    High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial.

    Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowski T.

    Ann Intern Med. 1994 Mar 1;120(5):375-81.PMID: 8304654 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity